Gene
CDKN1B
CDKN1B is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (37), Actionable biomarkers (2), Trial mentions (19), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDKN1B. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 8 of 11,460 | 0.07% |
| 2022 | 0 of 8,285 | 0.00% | 14 of 13,598 | 0.10% |
| 2021 | 0 of 8,692 | 0.00% | 18 of 15,045 | 0.12% |
| 2020 | 0 of 7,640 | 0.00% | 19 of 14,459 | 0.13% |
| 2019 | 1 of 7,300 | 0.01% | 16 of 12,159 | 0.13% |
| 2018 | 1 of 6,927 | 0.01% | 12 of 11,854 | 0.10% |
| 2017 | 0 of 6,558 | 0.00% | 27 of 11,595 | 0.23% |
Showing 10 of 37 years.
Assay-provider ledger (37)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Not a company | No clinical or analytical validation recorded for this pair | 1 | December 01, 2020 |
| Abbott Molecular | Diagnostic provider | Clinical validation | 1 | January 02, 2018 |
| OUTDO Biotech | Reagent supplier | Clinical validation | 1 | February 20, 2015 |
| DAKO | Unclassified | Clinical validation | 3 | November 05, 2013 |
| NovoCastra | Reagent supplier | Clinical validation | 2 | November 05, 2013 |
Showing 5 of 37 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDKN1B deletion | Cdk2/4 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| CDKN1B oncogenic mutation | Cdk2/4 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (19)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06331104 | Trial biospecimen (AACT) |
| NCT02037464 | Trial eligibility (AACT) |
| NCT02576665 | Trial eligibility (AACT) |
| NCT03454529 | Trial outcomes (AACT) |
| NCT00129376 | Trial outcomes (AACT) |
Showing 5 of 19 trial mentions.
Target-disease associations (734)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to isolated 17,20 lyase deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
Showing 5 of 734 associations.
Vendor sourcing (60)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple path... | View ClinVar record SCV002058546.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The CDKN1B c.356T>C; p.Ile119Thr variant (rs142833529, ClinVar Variation ID: 307664) is reported in the literature in multiple individuals affected with CDKN... | View ClinVar record SCV005877640.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV000664941.5 |
| Aventis Pharmaceuticals | Trial collaborator | Mentioned in trial textTrial free-text mention | p27 | View trial NCT00390429 |
| Boehringer Ingelheim (Germany) | Trial sponsor | Mentioned in trial textTrial free-text mention | p27 | View trial NCT00826267 |
Showing 5 of 60 sourcing records.
Trial-cited literature (299)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Genetic evaluation of pediatric pituitary adenomas and USP8-related genotype-phenotype correlations in Cushing's disease. | Pituitary | 2025 | 2 |
| MicroRNAs in Liver Cirrhosis: Diagnostic and Therapeutic Perspectives-A Comprehensive Review. | Journal of personalized medicine | 2025 | 1 |
| Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). | Blood cancer discovery | 2024 | 52 |
| Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. | Blood | 2024 | 11 |
| Biomarkers in Cancer Detection, Diagnosis, and Prognosis. | Sensors (Basel, Switzerland) | 2023 | 222 |
Showing 5 of 299 papers.
Protein variant mentions (24)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A121V | 1 | 2016 | PMID 26467025 |
| p.A123T | 1 | 2015 | PMID 25741868 |
| p.A55T | 1 | 2017 | PMID 28824003 |
| p.C148F | 1 | 2015 | PMID 25741868 |
| p.D136G | 2 | 2020 to 2022 | PMID 36149413, PMID 32232325 |
Showing 5 of 24 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.S125* | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Literature-extracted relations (67)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Sirolimus | Chemical | positive_correlate |
Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors. | 2013 |
| CISPLATIN | Chemical | positive_correlate |
Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs. | 2013 |
| Genistein | Chemical | positive_correlate |
The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. | 2012 |
| Genistein | Chemical | positive_correlate |
Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. | 2011 |
| PROPRANOLOL | Chemical | positive_correlate |
Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. | 2010 |
Showing 5 of 67 relation assertions.
Organizations publishing (302)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 21 | 2009 to 2025 |
| Harvard Medical School | Academic | 12 | 2000 to 2022 |
| Dana-Farber Cancer Institute | Other | 11 | 2000 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2001 to 2021 |
| Mayo Clinic | Hospital | 7 | 2008 to 2022 |
Showing 5 of 302 organizations.
Where CDKN1B appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
659 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.